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Abstract Huntington’s disease (HD) is an inherited neu-
rodegenerative disorder characterized by motor, cognitive
and behavioral disturbances, caused by the expansion of a
CAG trinucleotide repeat in the HD gene. The CAG allele
size is the major determinant of age at onset (AO) of motor
symptoms, although the remaining variance in AO is highly
heritable. The rs7665116 SNP in PPARGC1A, encoding the
mitochondrial regulator PGC-1, has been reported to be a
signiWcant modiWer of AO in three European HD cohorts,
perhaps due to aVected cases from Italy. We attempted to
replicate these Wndings in a large collection of (1,727) HD
patient DNA samples of European origin. In the entire
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cohort, rs7665116 showed a signiWcant eVect in the domi-
nant model (p value = 0.008) and the additive model
(p value = 0.009). However, when examined by origin,
cases of Southern European origin had an increased
rs7665116 minor allele frequency (MAF), consistent with
this being an ancestry-tagging SNP. The Southern Euro-
pean cases, despite similar mean CAG allele size, had a
signiWcantly older mean AO (p < 0.001), suggesting
population-dependent phenotype stratiWcation. When the
generalized estimating equations models were adjusted for
ancestry, the eVect of the rs7665116 genotype on AO
decreased dramatically. Our results do not support
rs7665116 as a modiWer of AO of motor symptoms, as we
found evidence for a dramatic eVect of phenotypic (AO)
and genotypic (MAF) stratiWcation among European
cohorts that was not considered in previously reported asso-
ciation studies. A signiWcantly older AO in Southern
Europe may reXect population diVerences in genetic or
environmental factors that warrant further investigation.
Introduction
Huntington’s disease (HD) is a neurodegenerative disorder
with classic symptoms that include progressive chorea,
motor deWcits, cognitive changes and dementia. Age at
onset (AO) of the overt symptoms is highly variable: while
some individuals show signs in the Wrst decade, others
remain asymptomatic even after 60 years of age, though in
most cases death follows on average about 17 years after
the Wrst symptoms. HD is inherited as an autosomal domi-
nant trait and is caused by the expansion of an unstable
CAG repeat, in the Wrst exon of the HD gene (now called
HTT), on chromosome 4p16.3 (The Huntington’s Disease
Collaborative Research Group 1993), resulting in an
expanded polyglutamine tract in the huntingtin protein.
The major determinant of AO in HD is the size of the
expanded CAG repeat allele (Lee et al. 2012), such that the
longer the repeat the earlier the onset of clinical symptoms,
though most HD cases occur in adulthood with about 40–45
CAG repeats. Repeat length alone explains about 70 % of
the variability in onset age (Duyao et al. 1993). The
remaining variance in AO (residual AO) is highly heritable
but remains unexplained. Nonetheless, recent genetic stud-
ies have nominated about 20 loci that may modify AO or
progression of HD. However, many of the speciWc poly-
morphisms assessed in multiple studies have failed to be
replicated, including attractive biological candidate genes
such as glutamate receptor, ionotropic kainate 2 (GRIK2),
apolipoprotein E (APOE) and brain-derived neurotrophic
factor (BDNF) (Rubinsztein et al. 1997; Metzger et al.
2006; Panas et al. 1999; Alberch et al. 2005; Di Maria et al.
2006).
One biologically compelling candidate thought to be
involved in HD pathogenesis is PPARGC1A, localized at
4p15.1-2, which encodes peroxisome proliferator-activated
receptor  coactivator 1 (PGC-1), a transcriptional regu-
lator of adaptive thermogenesis (Puigserver et al. 1998) and
mitochondrial respiration and oxidative stress (Puigserver
and Spiegelman 2003; St-Pierre et al. 2006). The lack of
PGC-1 expression produces an HD-like phenotype in
mice (Lin et al. 2004; Leone et al. 2005) and mutant, but
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not wild type, huntingtin down-regulates the expression of
PGC-1 and its target genes (Cui et al. 2006; Lin et al.
2004; Weydt et al. 2006). Moreover, three recent studies,
with DNA samples from European HD patients, mainly
from Italy and Germany, have reported an association of
PGC-1 with AO of HD symptoms (Che et al. 2011; Weydt
et al. 2009; Taherzadeh-Fard et al. 2009). Although diVer-
ent sets of PPARGC1A SNPs were included in these stud-
ies, one polymorphism (rs7665116), located at the 3-end
region of intron 2, was associated with a later AO in all
three studies, displaying a signiWcant eVect both in an addi-
tive and dominant model. Following these results, it was
reported that polymorphisms in PGC-1 downstream target
genes, namely nuclear respiratory factor 1 (NRF1) and
mitochondrial transcription factor A (TFAM), may inXu-
ence the AO in HD (Taherzadeh-Fard et al. 2011). Given
that results based on analyses of the PPARGC1A rs7665116
SNP are motivating a broader range of research into the
functional basis of the eVect, the aim of the present study
was to attempt to replicate the association of this SNP with
AO, in a much larger cohort of 1,727 HD patients of diVer-
ent European populations.
Methods
Subjects
We analyzed 1,929 HD patients with known AO of overt
motor symptoms. The DNA samples were from subjects
involved in long-term genetic studies from collaborating
investigators (HD-MAPS), the HD observational study
COHORT and from the Harvard Tissue Resource Center
Bank (McLean’s Hospital, Belmont MA) and the National
Neurological Research Bank (VAMC Wadsworth Division,
Los Angeles CA). These studies included related individu-
als [from 1,676 diVerent families deWned either based on
the likelihood of genetic similarity from genome-wide
genotyping information (Western European samples) or
membership in nuclear (parents and children) families
(Southern European samples)]. Of these, 934 were self-
reported as originally from Southern European countries
(263 from Portugal, 664 from Italy, 5 from Spain and 2
from Greece), the rest of the cases had unconWrmed or no
geographical origin data. 1,020 of these were genotyped
using the GeneChip Human Mapping 500K Array Set
(AVymetrix) at the Broad Institute of Harvard and MIT as
part of a genome-wide scan for HD genetic modiWers.
Genotyping
The HD CAG repeat length was determined by a polymer-
ase chain reaction (PCR) ampliWcation assay, using Xuores-
cently labeled primers, as previously described (Warner
et al.  1993). The size of the fragments was determined
using the ABI PRISM 3730xl automated DNA Sequencer
(Applied Biosystems, Foster City, CA, USA) and GeneM-
apper version 3.7 software. A set of HD CAG alleles, deter-
mined by DNA sequencing, were used as standards.
Genotyping of the PGC-1 polymorphism (rs7665116) was
performed by real-time PCR using the commercially avail-
able Taqman Genotyping probe (Applied Biosystems, Fos-
ter City, CA, USA) carried out on the LightCycler® 480
(Roche Diagnostics, Mannheim), following manufac-
turer’s instructions.
Statistics
For the 1,020 samples with whole-genome genotyping,
PCA was carried out using PLINK v1.05 (http://
pngu.mgh.harvard.edu/Purcell/plink/) (Purcell et al. 2007)
in order to determine the genetic ancestry of these individu-
als. BrieXy, genotypes of HD samples were combined with
HapMap Phase 2 data (CEPH, Yoruba, Han-Chinese and
Japanese populations) for pairwise IBD estimation and sub-
sequent IBS clustering.
To assess diVerences in the mean motor AO among
Western and Southern European samples, we used the gen-
eral estimating equation (GEE), thereby adjusting for
related samples. Multivariate analyses were generated
using GEE to assess the eVect of the rs7655116 SNP at the
PGC-1 gene with HD residual motor onset, adjusting for
familial correlation. Residual motor onsets were computed
as the diVerence between the observed and expected age of
onset and were standardized to a mean of zero and standard
deviation of one. The weighted GEE was computed assum-
ing an independent correlation structure and using the
robust estimator of the variance to account for familial rela-
tionships. All statistical analyses were performed using
PASW Statistics (version 18).
Results
We genotyped a collection of 1,929 HD DNA samples,
with known HD CAG allele sizes and known age at onset
of motor symptoms, for the PPARGC1A rs7665116 poly-
morphism. The observed genotype frequency of this SNP
was in Hardy–Weinberg equilibrium. Since, in two of the
previous reports, the association with AO was primarily
observed in HD patients of Italian ancestry (Che et al.
2011; Weydt et al. 2009); we split our large cohort by
ancestry into either Southern European or Western Euro-
pean HD cases. The Southern European HD cases (n = 934)
consisted of self-reported Portuguese (n =2 6 3 ) ,  I t a l i a n
(n =6 6 4 ) ,  S p a n i s h  ( n = 5) and Greek (n = 2) HD cases. The1836 Hum Genet (2012) 131:1833–1840
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Western European HD cases were chosen from amongst
another 1,020 HD patients by use of principal component
analysis (PCA) on available whole-genome genotyping data,
to infer their genetic background. The Wrst principal compo-
nent (PC1) distinguished Africans from non-Africans and the
second principal component (PC2) distinguished Africans
and Europeans from Asians (data not shown), and allowed us
to exclude from our analysis the few samples who had sig-
niWcant contribution of either Asian or African ancestry.
Among the remaining (n = 952) European cases, the Western
European cluster (n = 793) was deWned by overlap with the
US Northern-Western European origin CEPH (HapMap)
cluster, and consisted mainly of persons with self-reported
North-American origin (Canada and US) as well as French
and Irish. Thus, we had a total of 1,727 HD patients with
assigned ancestry; 934 Southern European and 793 Western
European (Table 1).
Remarkably, analysis of the clinical data for these 1,727
HD cases, which had CAG alleles ranging from 36 to 87
repeats, revealed that the self-reported Southern Europeans
(n = 934) had signiWcantly later onset of motor HD symp-
toms (p < 0.001), by 4–5 years, compared to the Western
European (n = 793), though the means/medians for HD
CAG repeat length were similar in both groups (Table 1).
Furthermore, the observed rs7665116 genotypes for sam-
ples from the Southern European countries revealed higher
minor allele frequency (MAF) (»17 %) when compared to
the Western European set (»12 %) (Table 1). These Wnd-
ings, together with the striking diVerences in the MAF of
this polymorphism among the diVerent HapMap popula-
tions, strongly suggested that population stratiWcation
might increase type I errors in the AO association analysis.
Finally, we have recently shown that the non-normal dis-
tribution of CAG allele size (and AO) also introduces error
in conventional statistical analysis (Lee et al. 2012). Even a
single CAG outlier sample, with a very long CAG repeat
and extremely young age at onset relative to all others, can
have a profound eVect on the Wnal result when testing for
the eVects of potential genetic modiWers (Lee et al. 2012).
Therefore, as a Wnal Wlter, we chose only the Southern and
Western European HD cases with CAG alleles in the 40- to
53-repeat range, shown previously to yield a statistically
well-behaved data set that conforms to the fundamental
assumptions of linear regression analysis (constant variance
and normally distributed error) (Lee et al. 2012).
As summarized in Table 1, these Wltering steps yielded a
total of 879 self-reported Southern European cases from
823 families and 749 Western European cases (matched by
use of PCA) from 620 diVerent families, with CAG repeats
ranging from 40 to 53 repeats. Notably, as observed for the
larger set of HD patients with a broader CAG repeat range,
in this Wnal set of 1,628 patients the self-reported Southern
Europeans had a signiWcantly older mean age at onset of
motor symptoms than Western Europeans (Table 1), which
was observed across the spectrum of CAG allele sizes
(Fig. 1), despite a similar mean/median HD CAG repeat
Table 1 Genetic and clinical data among European cases of Western and Southern origin
a Self-reported
b Genetic background conWrmed
Origin of samples 36-87 HD CAG range 40-53 HD CAG range
Number 
of samples
Mean HD 
CAG (median)
Mean Motor 
Onset (median)
rs7665116 
MAF
Number 
of samples
Mean HD 
CAG (median)
Mean Motor 
Onset (median)
rs7665116 
MAF
Southern Europeana 934 44.29 (43) 47.34 (48) 0.169 879 43.73 (43) 48.04 (48) 0.173
Western Europeanb 793 44.78 (44) 43.20 (43) 0.119 749 44.32 (44) 43.83 (43) 0.118
Total European 1,727 44.52 (43) 45.44 (45) 0.146 1,628 44.00 (43) 46.10 (46) 0.148
Fig. 1 Variance of age at motor onset for HD cases of Western and
Southern European origin. A box plot depicting the relationship of the
natural log-transformed age at onset of motor symptoms to the expand-
ed CAG allele size, for patients in the 40–53 CAG range, illustrating
that self-reported Southern Europeans had an older age at onset across
the spectrum of allele sizes. Circles are outliers deWned by a standard
quartile method (outside of 1.5 times interquartile range), some of
which could reXect errors in the motor AO data while others may rep-
resent true biological outliersHum Genet (2012) 131:1833–1840 1837
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size (Table 1). Furthermore, the rs7665116 MAF was
higher in the former relative to the latter Western European
patients (Table 1).
Using this Wnal set of 1,628 HD patients, we then per-
formed analysis to determine whether rs7665116 may con-
tribute to variance in HD motor onset not explained by the
length of the expanded CAG repeat. In order to adjust for
familial relationships, the eVect of the rs7665116 on resid-
ual motor onset was calculated using generalized estimat-
ing equations (GEE). In the unadjusted analysis, a
signiWcant association with later residual AO was observed
for both the additive genetic model ( = 0.090, p value =
0.009) and the dominant model ( = 0.113,  p value =
0.008) (Table 2). However, adjusting the analysis for
ancestry (Southern vs. Western European), in both the addi-
tive and the dominant models, produced a striking impact
on the eVect sizes ( decreased by »25 %) and the p values
(p increased »4£) (Table 2), thereby revealing that popula-
tion stratiWcation is a large contributor to an apparent
rs7665116 association.
Discussion
Previous studies have reported the presence of a common
polymorphism in PPARGC1A (rs7665116) that is associ-
ated with a delay in AO of HD motor symptoms in three
European HD cohorts (Che et al. 2011; Taherzadeh-Fard
et al. 2009; Weydt et al. 2009), primarily contributed by
patients from Italy. Our study, which involved a larger
collection of HD cases, did not provide strong evidence
for this SNP, and therefore, for PGC-1 as a modiWer of
HD motor onset, but did strongly support further investi-
gation of the factors that contribute to the striking diVer-
e n c e s  i n  A O  o f  m o t o r  s y m p t o m s  i n  ‘ S o u t h e r n
Europeans’.
The results of our study expose genetic ancestry as a crit-
ical factor in HD association studies. It is expected that a
disease-associated polymorphism may have varying eVects
in diVerent populations, but the variation in minor allele
frequency, across diVerent genetic backgrounds related to
ancestry may also be critical and should be taken into
account in genetic association analysis. Cases that are
poorly matched for genetic background may lead to false
positives in association studies. It is important to control for
ancestry by use of PCA or related methods, even in appar-
ently close related populations such as Europeans (Novem-
bre et al. 2008) where there is strong evidence of recent
population selection that has led to intra-European variation
in allele frequency (Price et al. 2008). This is particularly
important in studies using the CEPH-CEU panel as controls
since the genetic matching to diVerent populations may
diVer considerably in diVerent countries (Lao et al. 2008). It
is diYcult to accurately infer ancestry in candidate gene
association studies, leading to imperfect correction for
stratiWcation. However, with increasing availability of
genome-wide datasets, the assessment of population struc-
ture should become a common procedure for candidate
association studies.
Our study points out the dramatic eVect that population
stratiWcation can have in testing a candidate gene for an
association with disease phenotype. We found that the vari-
ation in rs7665116 minor allele frequency could lead to a
false positive, if genetic ancestry is not corrected for in the
analysis. The Southern European cases seem to be diVerent
genetically and clinically, in terms of age at diagnosis of
motor symptoms, from other European samples. By adjust-
ing for ancestry, we observed striking eVects on both the P
values (increased »4£) and eVect sizes (decreased by
»25 %). Even though the post-adjustment p values
remained nominally signiWcant, the dramatic reduction in
signiWcance occasioned by considering ancestry does not
Table 2 Multivariate correla-
tion of rs7665116 with residual 
age at motor onset
Model Standardized 
coeYcient
Standard 
error
95 % conWdence 
limits
p value*
Additive
PGC1 rs7665116
T–T vs. T–C vs. C–C 0.090 0.0348 0.022 0.158 0.009
PGC1 rs7665116 + ancestry
T–T vs. T–C vs. C–C 0.069 0.0345 0.001 0.136 0.047
WE vs. SE 0.208 0.0416 0.127 0.290 <0.001
Dominant
PGC1 rs7665116
T–T vs. T–C + C–C 0.113 0.0424 0.029 0.196 0.008
PGC1 rs7665116 + ancestry
T–T vs. T–C + C–C 0.089 0.0418 0.007 0.171 0.033
WE vs. SE 0.208 0.0415 0.127 0.289 <0.001
* p values were derived using 
GEE to account for familial rela-
tionships1838 Hum Genet (2012) 131:1833–1840
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lend conWdence to its being a true eVect and rather suggests
that it is due to insuYciently rigorous ancestry categoriza-
tion of the ‘Southern European’ set, which was based solely
on self-reporting rather than unbiased genome-wide geno-
typing data. Consistent with this interpretation, while this
manuscript was under review, an article by Soyal et al.
(2012) reported that no association of rs7651166 with AO
to Wrst symptom (not necessarily motor) was found in an
European cohort of 1,706 HD patients whose MAF for this
SNP closely resembled the MAF that we report for the
Western European samples in our study.
A remarkable Wnding from our analysis is the strong evi-
dence of later motor onset for HD patients originally from
Southern European countries (Portugal and Italy), which
have a reported onset of motor symptoms that is 4–5 years
later than that of HD patients from other European regions,
despite similar mean/median CAG allele size. This striking
diVerence may reXect population diVerences elsewhere in
the genome, since extensive genome-wide SNP analyses
have shown that even though European populations share
much of their genetic background, they also exhibit a nota-
ble degree of non-sharing (ancestry) (Lao et al. 2008;
Novembre et al. 2008). It’s important to note that in addi-
tion to genetic background diVerences, a number of other
factors may contribute to the diVerence in age at onset. One
possibility is environmental inXuences, for example, diVer-
ences related to lifestyle, or perhaps types of medication. A
meta-analysis study has found evidence that people who
adhere to a Mediterranean Diet appear to have a reduced
risk of developing Parkinson’s and Alzheimer’s disease
(SoW et al. 2008), and altered Alzheimer’s disease course
(Scarmeas et al. 2007). A recent observational study of HD
in Europe has shown that Southern European (and Polish)
clinicians prescribed anti-dyskinetic medication more fre-
quently than clinicians in other European regions (Orth
et al.  2010). Another environment related factor that is
likely to contribute are the criteria and procedures for diag-
nosing HD, which may diVer in diVerent cultures. It is now
important to understand which of many potential popula-
tion-speciWc genetic and/or environmental factors are asso-
ciated with later reported AO of motor symptoms in
Southern Europeans.
Conclusion
The results of our study do not provide strong evidence for
PPARGC1A SNP rs7665116, and therefore, for PGC-1, as
a modiWer of age at onset of HD motor symptoms. How-
ever, we have found evidence of a signiWcantly later age at
onset of motor symptoms in Southern European countries,
which may reXect genetic eVects and/or environmental
(lifestyle, diagnosis) factors that should be further explored.
Our data strongly illustrate the false contribution that popu-
lation stratiWcation may make in a candidate gene associa-
tion study, while providing genetic evidence that the
contribution of PGC-1 as a modiWer of the disease process
that leads to onset of HD motor symptoms may not be sig-
niWcant.
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